Utilization of breath methane levels for SIBO assessment is controversial largely due to a lack of validation related to diagnostic specifics such as timing and magnitude of increase; however, CH4 measurements are increasingly obtained to address other clinical questions. Recent evidence has associated CH4 production with the pathogenesis of common clinical conditions, such as obesity, irritable bowel syndrome (IBS), and constipation.
- The peer-reviewed literature suggests an association with certain clinical conditions and methanogen overgrowth at levels as low as 3 ppm, CH4 values between 3 and 9 may indicate the need for clinical intervention in the symptomatic patient.
- ELEVATED BASELINE - An elevated baseline may be a more common pattern with CH4 positive tests primarily due to the ability of methanogenic organisms to ferment in the absence of an ingested carbohydrate substrate.
Methane gas itself may slow intestinal transit, and patients with CH4-predominant bacterial overgrowth have been found to be five times more likely to have constipation compared to individuals with H2 - predominant overgrowth. Moreover, the severity of constipation has been found to directly correlate with the CH4 level.
Risk factors:
Decreased intestinal motility is a key factor in the development of SIBO and its recurrence. Out of all the diseases and disorders associated with SIBO, 90% of cases involve either small intestinal motility disorders and/or chronic pancreatitis.
The migrating motor complex (MMC) describes the waves of electromechanical activity that sweep through the intestines in regular cycles between meals. The MMC triggers waves that move non-digestible substances through the gastrointestinal tract from the stomach distally to the terminal ileum. In addition, the MMC is responsible for moving bacteria from the small intestine to the large intestine, as well as inhibiting the migration of colonic bacteria into the terminal ileum. Any disorder that impairs MMC function can be a risk factor for SIBO. Gastroenteritis that leads to post-infectious IBS-D is thought to be a risk factor for SIBO. Campylobacter jejuni, Salmonella, E. coli, and Shigella produce cytolethal distending toxin (CDT), and the host can produce an autoimmune response that damages the pacemaker cells for the MMC, resulting in decreased MMC activity. Other key SIBO risk factors include conditions that result in immunocompromise, decreased bacteriostatic digestive secretions (HCl, pancreatic enzymes, bile acids), and ileocecal valve dysfunction.
Complications of SIBO:
Because SIBO is not consistently characterized by the same species, different symptoms or complications may result, depending on the organisms that are present and their specific function in the GI tract. SIBO can result in damage to the small intestinal mucosa leading to malabsorption and intestinal permeability. Microscopic inflammatory changes in the lamina propria and villous atrophy are common. Destruction of the intestinal mucosa can result in reduced disaccharidase function and increased intraluminal bacterial carbohydrate degradation, causing SIBO symptoms. The bacteria themselves can consume nutrients, leading to micronutrient deficiencies, and deconjugate bile acids, leading to fat and fat-soluble vitamin malabsorption. Bacteria can produce toxic substances resulting in increased serum endotoxin, stimulating inflammatory cytokine production.
SIBO complications include:
- Weight loss
- Steatorrhea
- Vitamin/mineral deficiency
» Fat-soluble vitamins (A,D,E,K)
» Vitamin B12
» Iron
- Hypoproteinemia/hypoalbuminemia
- Bile acid deficiency
- Anemia
- Osteoporosis
- Neuropathies
------------------
References:
Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. The American journal of gastroenterology. May 2017;112(5):775-784. [PubMed]
Chatterjee S, Park S, Low K et al. The degree of breath methane production in IBS correlates with the severity of constipation. Am J Gastroenterol 2007;102:837–841. [PubMed]
Attaluri A, Jackson M, Valestin J et al. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol 2010;105:1407–1411. [PubMed]
Hwang L, Low K, Khoshini R et al. Evaluating breath methane as a diagnostic test for constipation-predominant IBS. Dig Dis Sci 2010;55:398–403. [PubMed]
Kunkel D, Basseri RJ, Makhani MD et al. Methane on breath testing is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci 2011;56:1612–1618. [PubMed]
Low K, Hwang L, Hua J et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol 2010;44:547–550. [PubMed]
Pimentel M, Chang C, Chua KS et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci 2014;59:1278–1285. [PubMed]
Rezaie A, Pimentel M, Rao SS. How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. Curr Gastroenterol Rep 2016;18:8. [PubMed]
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.